Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201606-15 Development of anti-PD-L1 therapeutic antibody for cancer immunotherapy(Oncology, Protein) [11.01.2016]

PRINT

Development and Market Objectives

The Development of novel Immuno-oncology therapeutic antibody which targets immune-checkpoint inhibitor ‘PD-L1’ with high anti-cancer efficacy and low immune toxicity

Unmet Medical Need & Target Patients

Target patients : metastatic Non-Small Cell Lung Cancer patients


Unmet Medical Need
-    About 80% of all NSCLC patients are diagnosed as advanced or metastatic stages at first cancer diagnosis, which usually come with very low cancer treatment efficacies 
-    2nd generation targeted therapy drugs have been quite successful for certain patients, however, almost every patients have experienced the recurrence of drug-resistant cancers after 5~8 months of treatment
-    Since 2012, Immuno-oncology antibody therapeutics have shown remarkable anti-cancer efficacies, however, so far, the highly efficacious biomarker has not been elucidated and the huge cost of Immuno-oncology antibody treatment have been such a hurdle for many NSCLC patients to experience the benefit of paradigm-shifting anti-cancer therapeutics

Status

We have confirmed in vitro, in vivo anti-cancer efficacies of our ‘KL001’, anti-PD-L1 antibody and confirmed well-behaved physico-chemical properties, binding specificities, comparative epitope analysis data with MPDL3280A(Roche PD-L1 antibody). Currently, candidate antibody optimizations are under investigation to get ready for the cell-line development

Intellectual Property

Korean patent and PCT applications are in preparation

Competitive Advantages

- Human & mouse cross-reactivity of KL001 can make rapid preclinical/clinical developments possible and mechanism studies, especially combination treatment studies with the other anti-cancer drugs or immune-modulating drugs in animal models will provide the advantages of using KL001 as a backbone drug in cancer treatment in early development stage
- Further investigations on the low immune toxicity property of ‘KL001’ antibody will provide the beneficial information for the long-term safety and low toxicity of KL001 as an unique immune-oncology therapeutic antibody
- Novel biomarker development studies using immunotherapy-experienced patient samples will provide a highly-efficacious immunotherapy biomarker system
    ???

Indication

Cancer

Research Period

2016.10.1-2018.10.31

Company

Scripps Korea Antibody Institute

Developmental Stage

Optimization

Additional Information

Contact Information

Contact
Address Company Name: Scripps Korea Antibody Institute
WebSite Homepage: http://www.skai.or.kr Contact Person: Dae Hee Kim. Ph.D.
E-mail: kimdh@skai.or.kr Contact: +82-33-250-8089

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code